Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedAug 17, 2026
DataAggregated Company Financials
Companies47
  • 7D-1.5%
  • 3M-1.6%
  • 1Y23.9%
  • YTD13.6%

Over the last 7 days, the Biotech industry has dropped 1.5%, driven by a pullback from Swedish Orphan Biovitrum of 2.2%. In the past year, the industry has gained 24%. Looking forward, earnings are forecast to grow by 33% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 17 Aug 2026SEK 241.5bSEK 40.1b-SEK 5,595,547,387.9032.9x-43.2x6x
Wed, 15 Jul 2026SEK 245.3bSEK 38.4b-SEK 6,219,055,359.7035.8x-39.4x6.4x
Fri, 12 Jun 2026SEK 239.5bSEK 38.4b-SEK 6,193,354,034.5937.8x-38.7x6.2x
Sun, 10 May 2026SEK 243.4bSEK 39.1b-SEK 5,092,580,387.0027.6x-47.8x6.2x
Tue, 07 Apr 2026SEK 228.4bSEK 38.5b-SEK 5,655,314,502.1118.2x-40.4x5.9x
Thu, 05 Mar 2026SEK 220.6bSEK 38.5b-SEK 5,717,572,834.2017x-38.6x5.7x
Sat, 31 Jan 2026SEK 227.8bSEK 38.3b-SEK 542,893,975.8835.4x-419.5x5.9x
Mon, 29 Dec 2025SEK 206.9bSEK 38.1b-SEK 556,386,495.8432.8x-371.8x5.4x
Wed, 26 Nov 2025SEK 207.3bSEK 37.7b-SEK 906,594,216.8232x-228.6x5.5x
Fri, 24 Oct 2025SEK 203.2bSEK 37.3b-SEK 1,233,595,599.3138.9x-164.8x5.5x
Sun, 21 Sep 2025SEK 196.9bSEK 36.4bSEK 3.0b31.1x65.1x5.4x
Tue, 19 Aug 2025SEK 188.5bSEK 35.9bSEK 2.8b28.1x67.4x5.2x
Thu, 17 Jul 2025SEK 189.9bSEK 35.2bSEK 2.4b29.8x78.3x5.4x
Sat, 14 Jun 2025SEK 184.6bSEK 35.2bSEK 2.2b29.4x83.4x5.2x
Mon, 12 May 2025SEK 189.9bSEK 34.0bSEK 929.2m33x204.4x5.6x
Wed, 09 Apr 2025SEK 175.6bSEK 33.7bSEK 766.9m29.1x229x5.2x
Fri, 07 Mar 2025SEK 199.4bSEK 33.7bSEK 594.1m33.9x335.7x5.9x
Sun, 02 Feb 2025SEK 225.7bSEK 33.1b-SEK 85,236,567.8059x-2647.4x6.8x
Tue, 31 Dec 2024SEK 218.2bSEK 33.0b-SEK 4,422,818,179.79157.3x-49.3x6.6x
Thu, 28 Nov 2024SEK 213.8bSEK 33.1b-SEK 4,553,366,282.42151x-47x6.5x
Sat, 26 Oct 2024SEK 223.4bSEK 33.2b-SEK 4,420,358,406.3533.9x-50.5x6.7x
Mon, 23 Sep 2024SEK 214.8bSEK 31.5b-SEK 5,544,590,338.5851.2x-38.7x6.8x
Wed, 21 Aug 2024SEK 206.9bSEK 31.4b-SEK 5,667,393,793.1549.7x-36.5x6.6x
Fri, 19 Jul 2024SEK 204.8bSEK 31.3b-SEK 5,445,571,272.6044.4x-37.6x6.5x
Sun, 16 Jun 2024SEK 191.6bSEK 30.6b-SEK 5,515,269,869.2838.2x-34.7x6.3x
Tue, 14 May 2024SEK 189.3bSEK 31.0b-SEK 5,215,978,060.2745.5x-36.3x6.1x
Thu, 11 Apr 2024SEK 180.1bSEK 29.8b-SEK 5,279,025,639.5563.4x-34.1x6x
Sat, 09 Mar 2024SEK 191.0bSEK 29.8b-SEK 5,646,599,210.3557.9x-33.8x6.4x
Mon, 05 Feb 2024SEK 180.8bSEK 28.8b-SEK 5,393,590,879.0061.5x-33.5x6.3x
Wed, 03 Jan 2024SEK 185.2bSEK 28.7b-SEK 1,197,622,927.0062.4x-154.6x6.5x
Fri, 01 Dec 2023SEK 172.1bSEK 28.7b-SEK 1,147,015,938.0057.3x-150x6x
Sun, 29 Oct 2023SEK 152.4bSEK 27.6b-SEK 1,701,256,191.0043x-89.6x5.5x
Tue, 26 Sep 2023SEK 160.5bSEK 27.4b-SEK 2,018,551,397.0049.5x-79.5x5.9x
Thu, 24 Aug 2023SEK 158.1bSEK 27.6b-SEK 1,544,721,654.0053.6x-102.4x5.7x
Price to Earnings Ratio

-102.4x


Total Market Cap: SEK 158.1bTotal Earnings: -SEK 1,544,721,654.00Total Revenue: SEK 27.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -38.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 13% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-1.02%
Healthcare0.00%
Biotech-1.53%
Biotech-1.53%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VITR VitrolifeSEK 90.952.2%
+SEK 264.1m		-32.5%PS3.6x
BONEX Bonesupport HoldingSEK 223.601.0%
+SEK 144.9m		-21.1%PE68.8x
BINV BioInvent InternationalSEK 24.907.6%
+SEK 115.2m		-32.7%PS7.5x
CURAS CurasightDKK 16.0010.7%
+DKK 74.9m		305.1%PB112.3x
HAMLET B Hamlet BioPharmaSEK 4.2014.3%
+SEK 93.3m		1.4%PS4191x

Latest News

MVIR
SEK 1.66
Medivir
7D
-7.8%
1Y
-15.6%
BIOA B
SEK 319.60
BioArctic
7D
-0.2%
1Y
36.3%
Narrative Update • Aug 12

BIOA B: Future Returns Will Depend On Biomarker And Trial Funding Risks

Analysts have raised their fair value estimate for BioArctic to SEK 280 from SEK 240, citing revised assumptions for revenue growth, profit margins and a lower projected future P/E multiple. Analyst Commentary on BioArctic Recent Street research on peers in adjacent therapeutic areas highlights how quickly sentiment can swing when trial outcomes challenge key scientific or commercial assumptions.
VITR
SEK 90.95
Vitrolife
7D
2.2%
1Y
-32.5%
Narrative Update • Aug 12

VITR: CEO Transition And Higher Margin Outlook Will Support Future Upside

Analysts have reset their price target for Vitrolife from SEK 215 to SEK 155. They adjusted assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple in their updated models.
SOBI
SEK 440.40
Swedish Orphan Biovitrum
7D
-2.2%
1Y
56.7%
EGTX
SEK 7.16
Egetis Therapeutics
7D
2.4%
1Y
28.5%
Narrative Update • Aug 07

EGTX: Overweight Rating And Higher Fair Value Will Support Future Upside

Analysts have raised their fair value estimate for Egetis Therapeutics from SEK 11.90 to approximately SEK 15.33, citing recent Street research support including a new SEK 23 price target and a positive rating initiation. What's in the News for Egetis Therapeutics Analysts highlight increased Street research attention on Egetis Therapeutics, including a newly cited SEK 23 price target.
XSPRAY
SEK 13.70
Xspray Pharma
7D
-4.5%
1Y
-68.6%
HNSA
SEK 39.16
Hansa Biopharma
7D
-1.2%
1Y
31.5%
VICO
SEK 11.20
Vicore Pharma Holding
7D
-0.5%
1Y
-2.1%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
BINV
SEK 24.90
BioInvent International
7D
7.6%
1Y
-32.7%
CURAS
DKK 16.00
Curasight
7D
10.7%
1Y
305.1%
BIOG B
SEK 113.00
BioGaia
7D
0.4%
1Y
20.0%
Narrative Update • Jul 21

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Analysts have trimmed their price target on BioGaia to SEK 152.50 from SEK 165.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News BioGaia New Sciences AB expanded the BioGaia Skincare portfolio with two new products, Gentle Balm to Milk Wash and Soothing Face & Body Lotion, and introduced an updated design across the full range, targeting babies and children with dry, sensitive and atopic prone skin.
BONEX
SEK 223.60
Bonesupport Holding
7D
1.0%
1Y
-21.1%
Narrative Update • Jul 20

BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions

Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.
SYNACT
SEK 19.94
SynAct Pharma
7D
6.0%
1Y
7.3%
DEX
SEK 7.15
Dextech Medical
7D
-10.6%
1Y
68.6%
SANION
SEK 12.89
Saniona
7D
-7.1%
1Y
54.4%